Lovelace Biomedical’s Advances in Toxicological Research to be Featured at the 56th Annual Meeting of the Society of Toxicology
Albuquerque, N.M., March 8, 2017 – Lovelace Biomedical, a not-for-profit preclinical contract research organization, today announced its participation in and presentation of scientific data at the Society of Toxicology (SOT) 56th Annual Meeting, held March 12 to 16 in Baltimore. This announcement comes on the heels of launching Lovelace Biomedical to partner with companies to cost-effectively and efficiently advance preclinical development of therapeutic compounds and novel technologies, highlighting its shift in focus and expertise in general and specialty toxicology.
“The SOT meeting brings together the nation’s top toxicologists to present the latest discoveries in this critical field,” said Jacob McDonald, Ph.D., Chief Scientific Officer at Lovelace Biomedical. “Our presentations and exhibition at this year’s conference underscore Lovelace’s continued dedication to serving our customers’ wide-ranging toxicological needs with efficiency and excellence.”
Lovelace Biomedical’s presentations showcase the unique research solutions that it develops for its pharmaceutical and biotechnology collaborators. These studies highlight Lovelace Biomedical’s strong capabilities and innovative solutions in animal model development, neurobehavioral endpoints, neurological evaluation (EEG) and inhalation toxicology, as well as vaccine and drug development. The presentations also demonstrate the company’s ability to provide results that are tailored and optimized for each collaborator and project. Copies of presentations can be obtained from Lovelace Biomedical’s booth at the conference’s ToxExpo (#2121).
Lovelace Biomedical’s booth will also feature its recently announced commitment to European standard housing of nonhuman primates at the conference’s ToxExpo. Scientific experts will be available to discuss the company’s robust bio-secure facility, its track record of outstanding quality, expansive capacity and industry-leading behavioral management and enrichment program.
About Lovelace Biomedical
Building on a history of pioneering science and technological innovation, Lovelace Biomedical is a contract research organization that helps pharmaceutical and biotechnology companies advance their discoveries—no matter how complex—into clinical testing and beyond. The organization leverages its multidisciplinary toolset to push the limits of preclinical research and fully understand every aspect of its clients’ investigational products. Lovelace Biomedical provides a unique scientific and logistical capacity to solve specialized challenges that other CROs are not equipped to handle, featuring expansive bio-secure facilities and ongoing access to industry-leading research experts and study directors. The team thrives on developing innovative programs and solutions for its clients, for difficult areas of drug development while delivering the same level of rigor and attention to seemingly straightforward studies that are just as critical to regulatory success. Visit www.lovelacebiomedical.org and follow on LinkedIn at www.linkedin.com/company/lovelace-biomedical or Twitter @LovelaceBio.
# # #
Erica A. Smith, Ph.D.
Senior Director, Commercial Sales and Marketing